Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Subcutaneous

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6,770 result(s) found for: Subcutaneous. Displaying page 1 of 339.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-005626-29 Sponsor Protocol Number: TR02ext Start Date*: 2015-01-21
    Sponsor Name:Trevi Therapeutics, Inc.
    Full Title: An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCL ER Tablets in Hemodialysis Patients with Uremic Pruritus
    Medical condition: Uremic Pruritis in Hemodialysis Patients
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-013455-30 Sponsor Protocol Number: AOBS-ECT-CH Start Date*: 2009-12-15
    Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
    Full Title: EFFICACY OF ELETTROPORATION COMBINED WITH BLEOMYCIN IN THE TREATMENT OF KELOIDS AND HYPERTROPHIC SCARS: A PILOT STUDY
    Medical condition: KELOIDS AND HYPERTROPHIC SCARS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040785 SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003396-21 Sponsor Protocol Number: V00034CR3071B Start Date*: 2005-10-18
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: LONG-TERM MANAGEMENT OF ATOPIC DERMATITIS WITH THE EMOLLIENT V0034 CR. A RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUPS, DOUBLE-BLIND STUDY IN INFANTS AND CHILDREN
    Medical condition: Patients presenting with an atopic dermatitis, out of flare at the inclusion.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10040785 LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) EE (Completed) FI (Completed) LV (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002803-18 Sponsor Protocol Number: V00034CR3041B Start Date*: 2005-10-18
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND EFFICACY STUDY OF THE EMOLLIENT V0034CR IN ADDITION TO A MODERATELY POTENT CORTICOSTEROID IN THE ACUTE PHASE OF TREATMENT OF ATOPIC DERMATITIS IN INFAN...
    Medical condition: Patient presenting with an atopic dermatitis.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10040785 LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) FI (Completed) EE (Completed) LV (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001753-26 Sponsor Protocol Number: DC0984LE401 Start Date*: 2013-07-25
    Sponsor Name:Pierre Fabre Dermo-cosmétique
    Full Title: Clinical and biophysics evaluation of the cutaneous modifications following the local use of a lotion containing 0,1 % of trétinoïne.
    Medical condition: Acne
    Disease: Version SOC Term Classification Code Term Level
    18.0 10040785 - Skin and subcutaneous tissue disorders 10000497 Acnes HLT
    18.0 10040785 - Skin and subcutaneous tissue disorders 10000496 Acne PT
    18.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    18.0 10040785 - Skin and subcutaneous tissue disorders 10040798 Skin appendage conditions HLGT
    Population Age: Adults Gender: Male
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-005625-22 Sponsor Protocol Number: TR02 Start Date*: 2015-01-12
    Sponsor Name:Trevi Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Hemodialysis Patients with Uremic Pruritis
    Medical condition: Uremic Pruritis in Hemodialysis Patients
    Disease: Version SOC Term Classification Code Term Level
    18.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2020-005108-21 Sponsor Protocol Number: DMB-3115-2 Start Date*: 2021-04-29
    Sponsor Name:Dong-A ST Co. Ltd.
    Full Title: A Randomized, Double-Blind, Multicentric, Parallel Group Therapeutic Equivalence Study Comparing Efficacy, Safety and Immunogenicity of Subcutaneous DMB-3115 and EU Sourced Stelara® in Patients wit...
    Medical condition: Moderate to Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10071117 Plaque psoriasis LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) CZ (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004508-23 Sponsor Protocol Number: EXP-1372 Start Date*: 2018-02-08
    Sponsor Name:LEO Pharma A/S
    Full Title: Capture of LEO 90100 medication usage with digital tracker and evaluation of efficacy in patients with psoriasis
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    20.0 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004504-33 Sponsor Protocol Number: BAT-2206-002-CR Start Date*: 2021-07-20
    Sponsor Name:Bio-Thera Solutions, Ltd.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Phase 3 Study to Compare Efficacy and Safety of BAT2206 with Stelara® in Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-002720-24 Sponsor Protocol Number: EXP-1377 Start Date*: 2017-10-17
    Sponsor Name:LEO Pharma A/S
    Full Title: Efficacy of twice daily application of LEO 124249 ointment 30 mg/g for 12 weeks on eyebrow alopecia areata. Exploratory Phase 2a
    Medical condition: Alopecia Areata
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002509-39 Sponsor Protocol Number: RD.03.SPR.102710 Start Date*: 2014-10-30
    Sponsor Name:GALDERMA R&D
    Full Title: Effect of Patient Education on Treatment Adherence and Satisfaction among Acne Patients Receiving Once-Daily EpiduoTM Gel Treatment in Primary Care Clinics
    Medical condition: Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    17.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002380-26 Sponsor Protocol Number: Somagel Start Date*: 2018-09-13
    Sponsor Name:SOCIETÀ ITALO BRITANNICA L. MANETTI - H. ROBERTS & C. PER AZIONI
    Full Title: Single-group, open study on the systemic bioavailability, safety and local tolerability of a new gel formulation of Somatoline¿ in 30 healthy women.
    Medical condition: Edematous fibrosclerotic panniculopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000426-66 Sponsor Protocol Number: 29BRC18.0036 Start Date*: 2018-07-13
    Sponsor Name:CHRU de Brest
    Full Title: Aprepitant versus Hydroxyzine en association avec les traitements cytoréducteurs pour les patients avec néoplasies myéloprolifératives souffrant d’un Prurit Aquagénique Persistant.
    Medical condition: néoplasies myéloprolifératives avec Prurit Aquagénique Persistant
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002398-22 Sponsor Protocol Number: CL-070-II-01 Start Date*: 2005-01-27
    Sponsor Name:IDEA AG
    Full Title: Double-blind, placebo-controlled study to investigate the efficacy and safety of IDEA-070 (ketoprofen in Transfersome®) in different dermatological diseases
    Medical condition: Patients with different dermatological diseases  Atopic eczema (MedDRA 6.0, LLT: 10003641)  Dishydrotic hand eczema (MedDRA 6.0, LLT: 10013913)  Plaque type psoriasis (MedDRA 6.0, LLT: 10050576)...
    Disease: Version SOC Term Classification Code Term Level
    6.0 10040833 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013320-23 Sponsor Protocol Number: 030(H)SC09143 Start Date*: 2009-10-14
    Sponsor Name:ANGELINI
    Full Title: A randomized, double-blind, placebo-controlled trial of benzydamine hydrochloride cream in the treatment of plaque psoriasis: a proof-of-concept and dose-finding study
    Medical condition: mild/severe plaque psorias
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040785 SOC
    9.1 10037153 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006191-30 Sponsor Protocol Number: IDI-ONC-3-20080901 Start Date*: 2008-12-20
    Sponsor Name:ISTITUTO DERMOPATICO IMMACOLATA
    Full Title: Biweekly Bevacizumab and weekly Carboplatin and Paclitaxel as II line therapy in advanced Malignant Melanoma patients: a phase II study
    Medical condition: patients with histologically confirmed progressive metastastic melanoma progressed after first line chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040785 SOC
    9.1 10027480 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004113-13 Sponsor Protocol Number: M602011070 Start Date*: 2020-08-17
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A prospective, randomized, double-blind, placebo-controlled, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the simultaneous treatment of ...
    Medical condition: Moderate to severe upper facial lines (horizontal forehead lines, glabellar frown lines, and lateral canthal lines)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10048042 Wrinkles LLT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10052609 Glabellar frown lines LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10052611 Crow's feet LLT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10040954 Skin wrinkling PT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001658-25 Sponsor Protocol Number: A6391002 Start Date*: 2005-06-16
    Sponsor Name:Pfizer Global Research and Development
    Full Title: An open label, two period crossover study to explore the safety, pharmacokinetics and pharmacodynamics of PHA-794428 after single subcutaneous injections in adult male patients with growth hormone ...
    Medical condition: AGHD Adult Growth Hormone Deficiency
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005944-22 Sponsor Protocol Number: 106670 Start Date*: 2006-02-21
    Sponsor Name:GlaxoSmithKline GmbH & Co. KG
    Full Title: Open, multicenter, randomised, controlled phase IIIb study evaluating the immunogenicity and safety of subcutaneous versus intramuscular administration of GlaxoSmithKline Biologicals’ combined meas...
    Medical condition: Active immunization of healthy children aged 11 to 21 months against measles, mumps, rebella and varicella diseases
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-005627-17 Sponsor Protocol Number: TR03 Start Date*: 2015-12-01
    Sponsor Name:Trevi Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCL ER Tablets in Prurigo Nodularis Patients
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 21:54:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA